IMPDH2 and breast cancer: Analysis of data from GSE34138, which is comprised of patients that were treated with dose dense Adriamycin + Cyclophosphamide, AC29, revealed that TNBC patients that achieved complete pathological response (pCR) after therapy had significantly lower levels of IMPDH2 as compared to those that remained with residual disease (RD) (Fig. 1C); conversely, pre-treatment IMPDH2 levels were non-predictive for HR-positive breast cancer patients (Fig. 1C).